High-dose interleukin 2 in patients with metastatic renal cell carcinoma with sarcomatoid features

Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study

(2016) David F. McDermott et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma

(2015) M. Dror Michaelson et al.   CANCER

Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Features

(2015) Daniel M. Geynisman   EUROPEAN UROLOGY

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial

(2015) Robert J. Motzer et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

(2015) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation

(2015) R. W. Joseph et al.   Cancer Immunology Research

A novel prognostic model for patients with sarcomatoid renal cell carcinoma

(2014) Ben Y. Zhang et al.   BJU INTERNATIONAL

The High-Dose Aldesleukin “Select” Trial: A Trial to Prospectively Validate Predictive Models of Response to Treatment in Patients with Metastatic Renal Cell Carcinoma

(2014) David F. McDermott et al.   CLINICAL CANCER RESEARCH

Sarcomatoid Renal Cell Carcinoma: A Comprehensive Review of the Biology and Current Treatment Strategies

(2012) B. Shuch et al.   ONCOLOGIST

Metastatic Sarcomatoid Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Therapy

(2008) Ali Reza Golshayan et al.   JOURNAL OF CLINICAL ONCOLOGY